Hengfeng Liao

Hengfeng Liao

Auto-generated profile, based on publicly available information

Hengfeng Liao

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
HLHengfeng Liao
Hengfeng Liao
YGYue Gao
Yue Gao
CLchunfang lian
chunfang lian
YZYun Zhang
Yun Zhang
BWBangyuan Wang
Bangyuan Wang
YLYuling Liu
Yuling Liu
Purpose: The aims of this study were to prepare a baicalein self-microemulsion with baicalein-phospholipid complex as the intermediate (BAPC-SMEDDS) and to compare its effects with those of conventional baicalein self-microemulsion (CBA-SMEDDS) on baicalein oral absorption and lymphatic transport. Methods: Two SMEDDS were characterized by emulsifying efficiency, droplet size, zeta potential, cloud point, dilution stability, physical stability, and in vitro release and lipolysis. Different formulations of 40 mg/kg baicalein were orally administered to Sprague-Dawley rats to investigate their respective bioavailabilities. The chylomicron flow blocking rat model was used to evaluate their lymphatic transport. Results: The droplet sizes of BAPC-SMEDDS and CBA-SMEDDS after 100x dilution were 9.6±0.2 nm and 11.3±0.4 nm, respectively. In vivo experiments indicated that the relative bioavailability of CBA-SMEDDS and BAPC-SMEDDS was 342.5% and 448.7% compared to that of free baicalein (BA). The AUC0–t and Cmax of BAPC-SMEDDS were 1.31 and 1.87 times higher than those of CBA-SMEDDS, respectively. The lymphatic transport study revealed that 81.2% of orally absorbed BA entered the circulation directly through the portal vein, whereas approximately 18.8% was transported into the blood via lymphatic transport. CBA-SMEDDS and BAPC-SMEDDS increased the lymphatic transport ratio of BA from 18.8% to 56.2% and 70.2%, respectively. Therefore, self-microemulsion not only significantly improves oral bioavailability of baicalein, but also increases the proportion lymphatically transported. This is beneficial to the direct interaction of baicalein with relevant immune cells in the lymphatic system and for proper display of its effects. Conclusion: This study demonstrates the oral absorption and lymphatic transport characteristics of free baicalein and baicalein SMEDDS with different compositions. This is of great significance to studies on lymphatic targeted delivery of natural immunomodulatory compounds.

20 June 2022 in Bioengineering & Translational Medicine
Verified
Journal Article
Open access
HLHengfeng Liao
Hengfeng Liao
JYJun Ye
Jun Ye
YGYue Gao
Yue Gao
CLChunfang Lian
Chunfang Lian
LLLu Liu
Lu Liu
YLYuling Liu
Yuling Liu
Cytokine storm is a phenomenon whereby the overreaction of the human immune system leads to the release of inflammatory cytokines, which can lead to multiple organ dysfunction syndrome. At present, the existing drugs for the treatment of cytokine storm have limited efficacy and severe adverse effects. Here, we report a lymphatic targeting self‐microemulsifying drug delivery system containing baicalein to effectively inhibit cytokine storm. Baicalein self‐microemulsion with phospholipid complex as an intermediate carrier (BAPC‐SME) prepared in this study could be spontaneously emulsified to form 12‐nm oil‐in‐water nanoemulsion after administration. And then BAPC‐SME underwent uptake by enterocyte through endocytosis mediated by lipid valve and clathrin, and had obvious characteristics of mesenteric lymph node targeting distribution. Oral administration of BAPC‐SME could significantly inhibit the increase in plasma levels of 14 cytokines: TNF‐α, IL‐6, IFN‐γ, MCP‐1, IL‐17A, IL‐27, IL‐1α, GM‐CSF, MIG, IFN‐β, IL‐12, MIP‐3α, IL‐23, and RANTES in mice experiencing systemic cytokine storm. BAPC‐SME could also significantly improve the pathological injury and inflammatory cell infiltration of lung tissue in mice experiencing local cytokine storm. This study does not only provide a new lymphatic targeted drug delivery strategy for the treatment of cytokine storm but also has great practical significance for the clinical development of baicalein self‐microemulsion therapies for cytokine storm.